| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Zhebeirine exhibits antitussive and expectorant properties. It may act on the respiratory system to facilitate bronchodilation, easing breathing difficulties. Its targets may include muscarinic receptors or other pathways involved in respiratory function.
|
|---|---|
| ln Vitro |
In vitro, Zhebeirine exhibits antitussive and expectorant properties. It is a steroidal alkaloid isolated from Fritillaria puqiensis. Detailed in vitro activity data, including IC50 values, are not reported.
|
| ln Vivo |
In vivo, Zhebeirine has antitussive and expectorant effects. It may facilitate bronchodilation. It has been used in traditional Chinese medicine for respiratory conditions. Animal studies are needed to further confirm its efficacy and safety.
|
| Enzyme Assay |
Cell-free assays for Zhebeirine: antitussive activity is assessed using models of cough reflex. Expectorant activity is assessed by measuring mucus secretion or airway fluid production. Bronchodilation is assessed by measuring airway smooth muscle relaxation in isolated tissue preparations. Receptor binding assays (e.g., muscarinic receptor binding) can be performed using radioligand binding assays.
|
| Cell Assay |
Cellular assays for Zhebeirine: airway smooth muscle cells or respiratory epithelial cells are cultured and treated with Zhebeirine at concentrations of 0.1-100 µM for 1-24 hours. Cell viability is measured by MTT assay. Mucus production is measured by ELISA or histochemical staining. Intracellular calcium levels are measured using fluorescent probes.
|
| Animal Protocol |
In vivo animal studies for Zhebeirine: animal models of cough (e.g., guinea pig cough model) or airway hyperreactivity would be used. Animals are administered Zhebeirine orally at doses of 10-50 mg/kg. Cough frequency, mucus production, and airway resistance are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Zhebeirine: as a steroidal alkaloid (MW 413.64), it may have moderate oral bioavailability. It is likely metabolized in the liver and excreted via the kidneys. Storage: powder at -20°C for up to 3 years. Soluble in DMSO.
|
| Toxicity/Toxicokinetics |
Toxicity of Zhebeirine: comprehensive toxicity data are limited. As a steroidal alkaloid, it may have significant toxicity at high doses. It is for research use only and not approved for clinical use.
|
| References | |
| Additional Infomation |
Zhebeirine has been reported in Fritillaria puqiensis, Fritillaria monantha, and Fritillaria unibracteata, and relevant data are available. See also: Zhebeirine (note moved to).
Zhebeirine is a research compound with potential applications in respiratory research. It is a steroidal alkaloid from Fritillaria puqiensis. Its mechanism involves antitussive and expectorant effects. No clinical trials or FDA approvals have been reported. |
| Molecular Formula |
C27H43NO2
|
|---|---|
| Molecular Weight |
413.63600
|
| Exact Mass |
413.329
|
| CAS # |
143120-47-2
|
| PubChem CID |
10597859
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
30
|
| Complexity |
707
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
C1C[C@]2(C)[C@@]3([H])C[C@]4([H])[C@@]([H])(CC[C@]5([H])[C@@H](C)[C@]6([H])CC[C@@H](C)CN6C[C@]54[H])[C@]3([H])CC(=O)[C@@]2([H])C[C@H]1O
|
| InChi Key |
MWBJDDYEYGDWCZ-PAYGNFRXSA-N
|
| InChi Code |
InChI=1S/C27H43NO2/c1-15-4-7-25-16(2)18-5-6-19-20(22(18)14-28(25)13-15)11-23-21(19)12-26(30)24-10-17(29)8-9-27(23,24)3/h15-25,29H,4-14H2,1-3H3/t15-,16-,17+,18-,19-,20-,21+,22-,23+,24-,25+,27-/m1/s1
|
| Chemical Name |
(1R,2S,6R,9S,10R,11S,14S,15S,18S,20S,23R,24S)-20-hydroxy-6,10,23-trimethyl-4-azahexacyclo[12.11.0.02,11.04,9.015,24.018,23]pentacosan-17-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4176 mL | 12.0878 mL | 24.1756 mL | |
| 5 mM | 0.4835 mL | 2.4176 mL | 4.8351 mL | |
| 10 mM | 0.2418 mL | 1.2088 mL | 2.4176 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
